BACKGROUND: Effective tuberculosis control is compromised by a lack of clarity about the timeframe of viable Mycobacterium tuberculosis shedding after treatment initiation under programmatic conditions. This study quantifies time to conversion from smear and culture positivity to negativity in unselected tuberculosis patients receiving standardized therapy in a directly observed therapy short-course (DOTS) program. METHODS: Longitudinal cohort study following up 93 adults initiating tuberculosis therapy in Lima, Peru. Baseline culture and drug susceptibility tests (DSTs) were performed using the MBBacT, proportion, and microscopic observation drug susceptibility (MODS) methods. Smear microscopy and MODS liquid culture were performed at baseline and weekly for 4 weeks then every other week for 26 weeks. RESULTS: Median conversion time from culture positivity to culture negativity of 38.5 days was unaffected by baseline smear status. Patients with fully susceptible tuberculosis had a median time to culture conversion of 37 days; 10% remained culture positive at day 60. Delayed culture conversion was associated with multidrug resistance, regardless of DST method used; non-multidrug resistance as defined by the proportion method and MODS (but not MBBacT) was also associated with delay. Persistent day 60 smear positivity yielded positive and negative predictive values of 67% and 92%, respectively, for detecting multidrug resistance. CONCLUSIONS: Smear and culture conversion in treated tuberculosis patients takes longer than is conventionally believed, even with fully susceptible disease, and must be accounted for in tuberculosis treatment and prevention programs. Persistent day 60 smear positivity is a poor predictor of multidrug resistance. The industrialized-world convention of universal baseline DST for tuberculosis patients should become the standard of care in multidrug resistance-affected resource-limited settings.
BACKGROUND: Effective tuberculosis control is compromised by a lack of clarity about the timeframe of viable Mycobacterium tuberculosis shedding after treatment initiation under programmatic conditions. This study quantifies time to conversion from smear and culture positivity to negativity in unselected tuberculosis patients receiving standardized therapy in a directly observed therapy short-course (DOTS) program. METHODS: Longitudinal cohort study following up 93 adults initiating tuberculosis therapy in Lima, Peru. Baseline culture and drug susceptibility tests (DSTs) were performed using the MBBacT, proportion, and microscopic observation drug susceptibility (MODS) methods. Smear microscopy and MODS liquid culture were performed at baseline and weekly for 4 weeks then every other week for 26 weeks. RESULTS: Median conversion time from culture positivity to culture negativity of 38.5 days was unaffected by baseline smear status. Patients with fully susceptible tuberculosis had a median time to culture conversion of 37 days; 10% remained culture positive at day 60. Delayed culture conversion was associated with multidrug resistance, regardless of DST method used; non-multidrug resistance as defined by the proportion method and MODS (but not MBBacT) was also associated with delay. Persistent day 60 smear positivity yielded positive and negative predictive values of 67% and 92%, respectively, for detecting multidrug resistance. CONCLUSIONS: Smear and culture conversion in treated tuberculosis patients takes longer than is conventionally believed, even with fully susceptible disease, and must be accounted for in tuberculosis treatment and prevention programs. Persistent day 60 smear positivity is a poor predictor of multidrug resistance. The industrialized-world convention of universal baseline DST for tuberculosis patients should become the standard of care in multidrug resistance-affected resource-limited settings.
Authors: P G Suárez; C J Watt; E Alarcón; J Portocarrero; D Zavala; R Canales; F Luelmo; M A Espinal; C Dye Journal: J Infect Dis Date: 2001-07-18 Impact factor: 5.226
Authors: A M Chavez Pachas; R Blank; M C Smith Fawzi; J Bayona; M C Becerra; C D Mitnick Journal: Int J Tuberc Lung Dis Date: 2004-01 Impact factor: 2.373
Authors: S G Franzblau; R S Witzig; J C McLaughlin; P Torres; G Madico; A Hernandez; M T Degnan; M B Cook; V K Quenzer; R M Ferguson; R H Gilman Journal: J Clin Microbiol Date: 1998-02 Impact factor: 5.948
Authors: David A J Moore; Carlton A W Evans; Robert H Gilman; Luz Caviedes; Jorge Coronel; Aldo Vivar; Eduardo Sanchez; Yvette Piñedo; Juan Carlos Saravia; Cayo Salazar; Richard Oberhelman; Maria-Graciela Hollm-Delgado; Doris LaChira; A Roderick Escombe; Jon S Friedland Journal: N Engl J Med Date: 2006-10-12 Impact factor: 91.245
Authors: L Caviedes; T S Lee; R H Gilman; P Sheen; E Spellman; E H Lee; D E Berg; S Montenegro-James Journal: J Clin Microbiol Date: 2000-03 Impact factor: 5.948
Authors: A Roderick Escombe; Clarissa Oeser; Robert H Gilman; Marcos Navincopa; Eduardo Ticona; Carlos Martínez; Luz Caviedes; Patricia Sheen; Armando Gonzalez; Catherine Noakes; David A J Moore; Jon S Friedland; Carlton A Evans Journal: Clin Infect Dis Date: 2007-04-09 Impact factor: 9.079
Authors: Richard Long; Karen Bochar; Sylvia Chomyc; James Talbot; James Barrie; Dennis Kunimoto; Peter Tilley Journal: Infect Control Hosp Epidemiol Date: 2003-11 Impact factor: 3.254
Authors: Grant Theron; Jason Limberis; Rouxjeane Venter; Liezel Smith; Elize Pietersen; Aliasgar Esmail; Greg Calligaro; Julian Te Riele; Marianna de Kock; Paul van Helden; Tawanda Gumbo; Taane G Clark; Kevin Fennelly; Robin Warren; Keertan Dheda Journal: Nat Med Date: 2020-06-29 Impact factor: 53.440
Authors: Christine Sekaggya-Wiltshire; Amrei von Braun; Mohammed Lamorde; Bruno Ledergerber; Allan Buzibye; Lars Henning; Joseph Musaazi; Ursula Gutteck; Paolo Denti; Miné de Kock; Alexander Jetter; Pauline Byakika-Kibwika; Nadia Eberhard; Joshua Matovu; Moses Joloba; Daniel Muller; Yukari C Manabe; Moses R Kamya; Natascia Corti; Andrew Kambugu; Barbara Castelnuovo; Jan S Fehr Journal: Clin Infect Dis Date: 2018-08-16 Impact factor: 9.079
Authors: A S Dharmadhikari; M Mphahlele; K Venter; A Stoltz; R Mathebula; T Masotla; M van der Walt; M Pagano; P Jensen; E Nardell Journal: Int J Tuberc Lung Dis Date: 2014-09 Impact factor: 2.373
Authors: J Z Metcalfe; S Makumbirofa; B Makamure; C Sandy; W Bara; P Mason; P C Hopewell Journal: Int J Tuberc Lung Dis Date: 2016-07 Impact factor: 2.373
Authors: Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon Journal: Clin Infect Dis Date: 2016-08-10 Impact factor: 9.079
Authors: Christoph Lange; Ibrahim Abubakar; Jan-Willem C Alffenaar; Graham Bothamley; Jose A Caminero; Anna Cristina C Carvalho; Kwok-Chiu Chang; Luigi Codecasa; Ana Correia; Valeriu Crudu; Peter Davies; Martin Dedicoat; Francis Drobniewski; Raquel Duarte; Cordula Ehlers; Connie Erkens; Delia Goletti; Gunar Günther; Elmira Ibraim; Beate Kampmann; Liga Kuksa; Wiel de Lange; Frank van Leth; Jan van Lunzen; Alberto Matteelli; Dick Menzies; Ignacio Monedero; Elvira Richter; Sabine Rüsch-Gerdes; Andreas Sandgren; Anna Scardigli; Alena Skrahina; Enrico Tortoli; Grigory Volchenkov; Dirk Wagner; Marieke J van der Werf; Bhanu Williams; Wing-Wai Yew; Jean-Pierre Zellweger; Daniela Maria Cirillo Journal: Eur Respir J Date: 2014-03-23 Impact factor: 16.671